title: [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
abstract: S-1 administration for 28 consecutive days followed by 14 days of rest (6-week cycle) is often chosen as second-line chemotherapy for advanced pancreatic cancer (PC), but it causes gastrointestinal toxicity. In comparison, in gastric cancer or head and neck cancer, S-1 administration for 14 consecutive days followed by a 7-day rest period (3-week cycle) reduced gastrointestinal toxicity. This study retrospectively evaluated the efficacy and safety of a 3-week S-1 schedule compared to a 6-week schedule in patients with gemcitabine (GEM)-refractory advanced PC. Fifty-seven patients were treated with the 6- week S-1 schedule and 68 patients were treated with the 3-week S-1 schedule. There were no statistical differences in overall survival (p=0.13) and progression-free survival (p=0.190). With regard to adverse events, the rates of nausea (p<0.01) and vomiting (p=0.04) were lower with the 3-week schedule than with the 6-week schedule. Thus, S-1 therapy with a 3- week schedule as second-line chemotherapy in patients with GEM-refractory advanced PC was associated with reduced gastrointestinal toxicity and similar efficacy, when compared to a 6-week schedule.
authors: Dept. of Pharmacy, National Cancer Center Hospital East.
authors: Hiroto
authors: H
authors: Tanaka
authors: Shuichi
authors: S
authors: Mitsunaga
authors: Misaki
authors: M
authors: Kobayashi
authors: Hideki
authors: H
authors: Funazaki
authors: Shiro
authors: S
authors: Katayama
authors: Akiko
authors: A
authors: Kuwahara
authors: Hiroyuki
authors: H
authors: Okuyama
authors: Hideaki
authors: H
authors: Takahashi
authors: Izumi
authors: I
authors: Ohno
authors: Satoshi
authors: S
authors: Shimizu
authors: Yasunari
authors: Y
authors: Sakamoto
authors: Shunsuke
authors: S
authors: Kondo
authors: Chigusa
authors: C
authors: Morizane
authors: Hideki
authors: H
authors: Ueno
authors: Takuji
authors: T
authors: Okusaka
authors: Atsushi
authors: A
authors: Ochiai
authors: Masafumi
authors: M
authors: Ikeda
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine